EW · Edwards Lifesciences

S&P 500 #227 · NYSE

Risiko 4/10 · MedTech Growth · $83.68 ▲ 0.77%

Kennzahlen

• Price $83.68
• Market cap $48.2B
• P/E (ttm) 49.81
• Div yield none
• 52-wk range $72.30 – $96.29
• Index rank #227 / —

Wichtigste Risiken

• TAVR market maturation / competition from Medtronic, Abbott (Market share) — MED
• CMS reimbursement rate reductions (Procedure economics) — LOW
• High premium multiple at ~49x trailing P/E (Downside in a risk-off move) — LOW
• EPS declined 73% YoY (one-time divestiture noise) (Reported earnings optics) — LOW

Fazit

Heart valve technology specialist near 52-week high on 14% revenue growth, leveraging aging population and expanding TAVR/TMTT procedures.

Interaktive Analyse öffnen → Teilen

Recherche, keine Anlageberatung.